GSK is increasingly confident that its anti-BCMA drug Blenrep could be returned to the US market, after revealing data from the DREAMM-8 trial of the drug in multiple myeloma at ASCO. Adding ...

GSK's Blenrep has nearly completed its winding road as the multiple myeloma drug receives approval for second-line us in the UK. The importance of biosimilars only continues to grow, driven by the ...

In a report released today, Jo Walton from UBS maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of ...

U.S. Food and Drug Administration (FDA) Commissioner Marty Makary announces the FDA’s intent to phase out the use of petroleum-based synthetic dyes in the nation’s food supply during a press ...